MetaCap

Lakefront Biotherapeutics (LKFT) vs NewAmsterdam Pharma N.V. (NAMS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lakefront Biotherapeutics (LKFT) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 8.6% versus a loss of 51.9%. Over five years, NAMS leads with a +88.0% price change compared with -31.8% for LKFT. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.21 billion vs $2.18 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LKFT+8.64%NAMS-51.89%
+17%-19%-55%
Nov 21, 20251 yearNov 20, 2026
LKFT-35.27%NAMS+87.47%
+339%+132%-75%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LKFT versus NAMS key metrics
MetricLKFTNAMS
Share price$33.31$18.41
Market cap$2.18B$2.21B
1-day change-0.24%-5.64%
YTD return+1.87%-47.52%
1-year return+8.64%-51.89%
5-year return-31.80%+88.05%
P/E ratio (TTM)2.39—
EPS (TTM)$13.94$-1.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$22.50M
Revenue growth (YoY)—-50.61%
Net income (latest FY)—$-203.82M
Operating margin—-1002.90%
Net margin—-905.74%
52-week high$36.24$42.21
52-week low$25.68$17.90
Distance from 52-week high-8.08%-56.38%
Analyst consensusholdstrong_buy
Avg. price target upside-7.39%+174.85%
Average volume280.49K1.66M
Shares outstanding65.48M119.93M
Employees196100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LKFT has outperformed NAMS by 60.5 percentage points over the past year.

About Lakefront Biotherapeutics

LKFT stock →

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees

About NewAmsterdam Pharma N.V.

NAMS stock →

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

LKFT vs NAMS FAQ

Which is bigger, Lakefront Biotherapeutics or NewAmsterdam Pharma N.V.?

NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.21B compared with $2.18B for Lakefront Biotherapeutics (LKFT).

Which stock has performed better over the past year, LKFT or NAMS?

LKFT returned +8.64% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.

Are Lakefront Biotherapeutics and NewAmsterdam Pharma N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons